Project Grant K99AI201933
Award Date 8/25/26
Completion Date 7/31/28
Dollars Obligated $194K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Regents of the University of Michigan $411,078 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify novel antifungal compounds from symbiotic bacteria capable of combating drug-resistant Candida auris. The research exploits symbiotic bacteria—organisms that co-exist with and benefit their eukaryotic hosts—as a source of antifungal molecules with low mammalian toxicity. The...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on April 1, 2026 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project examines the role of organelle membrane contact sites in macrophage antifungal immune responses, with particular focus on Candida albicans infection. Preliminary data indicate that the endoplasmic reticulum stress sensor IRE1A...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $233,250 in project grant funding (R21AI199182) on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to characterize the evolution of multidrug resistance in Candida auris, a newly emerged fungal pathogen associated with invasive candidiasis worldwide and mortality rates approaching 68 percent. The recipient will prospectively...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $713,383 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms and dynamics of genome plasticity in antifungal-resistant Candida species. The project addresses the molecular drivers of antifungal resistance in Candida albicans, Candida glabrata, and Candida auris through examination of large DNA amplification events, aneuploid...
- The National Institute of Allergy and Infectious Diseases awarded Texas A&M University System Health Science Center $192,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into novel antifungal therapeutics. The award funds structure-based design, synthesis, and validation of small molecule inhibitors targeting fungal SEC14 phosphatidylinositol transfer proteins as a strategy to combat multi-drug-resistant fungal infections,...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $172,028 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop cellular glue therapeutics that enhance innate immune responses against fungal pathogens, particularly Candida auris. The research spans two phases. During the R21 phase (through May 31, 2028), MIT will generate multifunctional compounds that simultaneously bind to glycan-binding...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $245,233 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and characterize a previously unknown family of pore-forming toxins in non-albicans Candida species. The project clones, expresses, and tests the cytotoxic activity of aerolysin-like toxin (KTO) genes detected in Candida species against a broad panel of potential fungal competitors and...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $225,628 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify genetic mechanisms of polyene resistance in Candida glabrata using saturating transposon mutagenesis coupled with next-generation DNA sequencing (TN-SEQ). The project will implement TN-SEQ to mutate and barcode every gene in C. glabrata and profile resistance to three approved...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Davis $191,916 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support project grant K08AI199044, a genetics approach to Candida albicans gastrointestinal colonization resistance. The research addresses invasive candidiasis, which occurs when C. albicans enters the bloodstream and disseminates throughout the body with mortality approaching 50 percent....
- The National Institute of Allergy and Infectious Diseases awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $449,625 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study regulation of Candida albicans biofilm formation on central venous catheters. The project investigates how transcription factor networks control Candida albicans biofilm development under physiological bloodstream conditions. Candida albicans...